# The Information Theory of Aging: research update

Dated 5 October 2026. Local prepublication addendum; archived grade unchanged.

Partial reprogramming can change molecular age measures and selected functional outcomes in models. Whether these effects establish epigenetic information loss as the necessary cause of normal aging is distinct from showing rejuvenation-associated changes, and toxicity depends strongly on protocol and tissue.

## Research timeline

Electronic year is used where recorded; issue year is retained in each source card. The chronology is selected, not exhaustive, and does not establish priority or causation.

| Year | Primary study | Design and finding | Inference limit |
|---|---|---|---|
| 2014 | [Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation.](https://pubmed.ncbi.nlm.nih.gov/24529372/) | In vivo interrupted reprogramming. Reprogramming perturbation produced dysplastic tumours with altered epigenetic regulation. | Epigenetic plasticity can cause harm; marker resetting is not intrinsically beneficial. |
| 2016 | [In Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming.](https://pubmed.ncbi.nlm.nih.gov/27984723/) | Cyclic partial reprogramming in mice. Age-associated measures improved and survival increased in a premature-aging model. | Progeroid survival and injury recovery do not establish general human aging reversal. |
| 2020 | [Reprogramming to recover youthful epigenetic information and restore vision.](https://pubmed.ncbi.nlm.nih.gov/33268865/) | Retinal OSK expression in mice. Axon/vision recovery and youthful molecular patterns required TET1/TET2. | A tissue-specific dependency does not demonstrate organism-wide aging mediation. |
| 2022 | [Multi-omic rejuvenation of naturally aged tissues by a single cycle of transient reprogramming.](https://pubmed.ncbi.nlm.nih.gov/35235716/) | Single-cycle reprogramming of aged mice. Several tissue molecular and serum measures shifted toward younger profiles. | Molecular reversal is not automatically a durable functional or survival benefit. |
| 2022 | [Multi-omic rejuvenation of human cells by maturation phase transient reprogramming.](https://pubmed.ncbi.nlm.nih.gov/35390271/) | Transient reprogramming of human fibroblasts. Molecular age measures and selected fibroblast functions improved. | Cultured cells are not whole-person healthspan. |
| 2023 | [Loss of epigenetic information as a cause of mammalian aging.](https://pubmed.ncbi.nlm.nih.gov/36638792/) | Induced epigenome-change mouse system. DNA-break repair perturbation produced aging-related phenotypes reversible by OSK. | An induced repair system does not isolate the necessary initiating cause of natural aging. |
| 2023 | [In vivo reprogramming leads to premature death linked to hepatic and intestinal failure.](https://pubmed.ncbi.nlm.nih.gov/38012287/) | Continuous in vivo OSKM toxicity study. Hepatic and intestinal dysfunction contributed to early mortality. | Tissue distribution and induction duration determine harms and apparent benefit. |
| 2024 | [Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in Aged Mice.](https://pubmed.ncbi.nlm.nih.gov/38381405/) | AAV-OSK aged-mouse study. Late-life treatment improved frailty and reported remaining survival. | Remaining-life effects, sample/model scope and vector controls require replication. |
| 2026 | [In Vivo Chemical Reprogramming Is Associated With a Toxic Accumulation of Lipid Droplets Hindering Rejuvenation.](https://pubmed.ncbi.nlm.nih.gov/41589348/) | Chemical reprogramming in aged mice. Higher-dose treatment caused lipid accumulation, stress and severe toxicity. | Chemical-cocktail toxicity cannot be generalized to every genetic reprogramming protocol. |

## Research gaps

### G1: Is epigenetic information loss necessary for normal aging?

Evidence anchors: [P36638792](https://pubmed.ncbi.nlm.nih.gov/36638792/), [P33268865](https://pubmed.ncbi.nlm.nih.gov/33268865/), [P27984723](https://pubmed.ncbi.nlm.nih.gov/27984723/).

Competing explanation: Repair stress, cell-state change or other damage may produce similar age markers.

Discriminating test and controls: Selective epigenetic perturbations and rescue with measured genome damage and cell composition; test naturally aged animals independently of induced injury.

### G2: Do molecular clocks track the treatment’s functional benefit?

Evidence anchors: [P35235716](https://pubmed.ncbi.nlm.nih.gov/35235716/), [P35390271](https://pubmed.ncbi.nlm.nih.gov/35390271/), [P38381405](https://pubmed.ncbi.nlm.nih.gov/38381405/).

Competing explanation: Clocks may directly respond to reprogramming without measuring durable tissue performance.

Discriminating test and controls: Prespecified multi-tissue functions, frailty and survival alongside orthogonal clocks; examine discordant molecular and functional responders.

### G3: Which component and cell state mediates recovery?

Evidence anchors: [P33268865](https://pubmed.ncbi.nlm.nih.gov/33268865/), [P36638792](https://pubmed.ncbi.nlm.nih.gov/36638792/), [P35390271](https://pubmed.ncbi.nlm.nih.gov/35390271/).

Competing explanation: Regeneration, clonal selection or altered cell mixture may mimic restoration of a retained youthful programme.

Discriminating test and controls: Lineage tracing, single-cell multi-omics and pathway-specific blockade/rescue with identity and functional measures.

### G4: What delivery window yields durable benefit without loss of identity or toxicity?

Evidence anchors: [P24529372](https://pubmed.ncbi.nlm.nih.gov/24529372/), [P38012287](https://pubmed.ncbi.nlm.nih.gov/38012287/), [P41589348](https://pubmed.ncbi.nlm.nih.gov/41589348/), [P38381405](https://pubmed.ncbi.nlm.nih.gov/38381405/).

Competing explanation: Dedifferentiation, tissue failure or proliferative risk may offset short-term molecular improvement.

Discriminating test and controls: Independent dose/tissue/duration comparisons with long follow-up, tumour surveillance, functional endpoints and matched vector/vehicle controls.

## Methods and access

Case-specific Consensus records assisted gap discovery, chronology and targeted paper questions. Shared template wording about an amyloid-specific Deep follow-up is not evidence of a Deep run for this topic; the dated source records establish the actual use and access limits. Primary identifiers, selected abstract passages, correction notices and available primary-body passages were cross-checked. Generated absence cells, duplicate milestones and unsupported access claims were rejected.

This focused addendum does not establish 50–70 complete primary Methods/Results examinations per review. Baseline reading receipts and scores retain their original scope.

Checked timeline sources: 9; selected full-text checks: 0; abstract-excerpt checks: 9; metadata-only historical anchors: 0. Complete papers examined in this update: 0.

Historical scorecards declare schema 5.4. This enrichment uses HSEF v5.3 causal distinctions without retrospectively relabelling or rescoring those files.

Targeted paper-check scope: Primary abstract/metadata checked. Additional Consensus full-text details remain provider-reported because a separately readable body was unavailable in this update.